EXEL

59.51

0.52% -0.31

Dopo l'orario di chiusura: 59.51

Exelixis Inc (EXEL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$59.82

Aprire:

$60

Volume 24 ore:

2.62M

Relative Volume:

1.07

Capitalizzazione di mercato:

$14.75B

Reddito:

$2.38B

Utile/perdita netta:

$833.42M

Rapporto P/E:

19.72

EPS:

3.0172

Flusso di cassa netto:

$917.69M

1 W Prestazione:

+2.02%

1M Prestazione:

+6.04%

6M Prestazione:

+32.36%

1 anno Prestazione:

+54.81%

Intervallo 1D:

$58.59

$60.00

Intervallo di 1 settimana:

$57.88

$61.66

Portata 52W:

$33.76

$61.66

Exelixis Inc Stock (EXEL) Company Profile

Nome

Exelixis Inc

Settore

Healthcare (1051)

Industria

Biotechnology (593)

Telefono

(650) 837-7000

Indirizzo

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Dipendente

1,077

Cinguettio

@exelixisinc

Prossima data di guadagno

2026-11-03

Ultimi documenti SEC

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, MRNA, REGN, ARGX, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EXEL Exelixis Inc	59.51	14.75B	2.38B	833.42M	917.69M	3.0172
VRTX Vertex Pharmaceuticals Inc	485.22	122.98B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	216.25	86.33B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	753.12	77.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	802.64	50.47B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.44	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-08-19	Iniziato	BMO Capital Markets	Market Perform
2026-08-06	Downgrade	Leerink Partners	Outperform → Market Perform
2026-06-25	Ripresa	Truist	Hold
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	Downgrade	BofA Securities	Neutral → Underperform
2025-11-18	Iniziato	Wolfe Research	Peer Perform
2025-11-03	Downgrade	Guggenheim	Buy → Neutral
2025-10-21	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-09-19	Ripresa	Barclays	Equal Weight
2025-09-17	Ripresa	Barclays	Equal Weight
2025-09-17	Iniziato	Goldman	Buy
2025-07-08	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Aggiornamento	Stephens	Equal-Weight → Overweight
2025-02-24	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-01-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Downgrade	Oppenheimer	Outperform → Perform
2024-12-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Downgrade	BofA Securities	Buy → Neutral
2024-10-16	Reiterato	RBC Capital Mkts	Outperform
2024-09-19	Iniziato	UBS	Neutral
2024-04-11	Downgrade	Barclays	Overweight → Equal Weight
2023-12-19	Iniziato	BTIG Research	Buy
2023-12-15	Iniziato	Citigroup	Buy
2023-09-26	Iniziato	H.C. Wainwright	Buy
2023-08-22	Reiterato	Oppenheimer	Outperform
2023-08-08	Iniziato	SVB Securities	Market Perform
2023-07-11	Ripresa	Morgan Stanley	Equal-Weight
2023-05-10	Ripresa	Piper Sandler	Overweight
2023-03-09	Iniziato	Wells Fargo	Overweight
2023-01-26	Iniziato	Credit Suisse	Outperform
2022-10-18	Iniziato	JMP Securities	Mkt Outperform
2022-06-24	Iniziato	BMO Capital Markets	Outperform
2021-11-19	Iniziato	Piper Sandler	Overweight
2021-11-03	Ripresa	Jefferies	Buy
2021-10-07	Iniziato	Jefferies	Buy
2021-08-06	Reiterato	H.C. Wainwright	Buy
2021-06-15	Iniziato	H.C. Wainwright	Buy
2021-05-18	Ripresa	Goldman	Sell
2021-03-31	Iniziato	Credit Suisse	Outperform
2021-03-12	Iniziato	Wolfe Research	Outperform
2020-03-04	Iniziato	Barclays	Overweight
2020-01-13	Iniziato	SunTrust	Buy
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-03-18	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Iniziato	Goldman	Neutral
2018-09-10	Iniziato	Morgan Stanley	Underweight
2018-05-11	Reiterato	Needham	Buy
2017-10-17	Reiterato	Needham	Buy
2017-10-17	Reiterato	RBC Capital Mkts	Outperform
2017-10-16	Reiterato	SunTrust	Buy
2017-09-22	Downgrade	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-09-12	Reiterato	Needham	Buy
2017-07-14	Iniziato	SunTrust	Buy
2017-03-31	Iniziato	Needham	Buy
2017-03-16	Iniziato	Oppenheimer	Perform
2017-02-28	Downgrade	Stifel	Buy → Hold
2016-11-03	Iniziato	Deutsche Bank	Buy
2016-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-09-15	Reiterato	Stifel	Buy

Mostra tutto

Exelixis Inc Borsa (EXEL) Ultime notizie

01:08 AM

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - Morningstar

01:08 AM

Oct 12, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - TradingView

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com South Africa

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com India

Oct 12, 2026

Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital - ChartMill

Oct 12, 2026

Oct 10, 2026

Virtus NFJ Mid-Cap Value Fund's Exelixis Inc(EXEL) Holding History - GuruFocus

Oct 10, 2026

Oct 09, 2026

Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says - marketscreener.com

Oct 09, 2026

RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating - Yahoo Finance

Oct 09, 2026

Oct 08, 2026

EXEL Maintained by RBC Capital -- Price Target Lowered to $45 - GuruFocus

Oct 08, 2026

Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance

Oct 08, 2026

Exelixis stock gets a higher Truist target at USD 54 - AD HOC NEWS

Oct 08, 2026

Oct 07, 2026